3 results
The objective of the study is to investigate how quickly and to what extent balovaptan is absorbed and eliminated from the body (pharmacokinetics) when it is administered in combination with rifampicin. It will also be investigated to what extent…
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.
The primary objective of this study is to investigate if single-inhaler triple therapy (SITT, in this study Trimbow®) is superior to multi-inhaler triple therapy (MITT, in this study Bevespi® and Qvar®) in terms of adherence to inhaled…